儿童急性淋巴细胞白血病幸存者发病率与死亡率降低:儿童癌症幸存者研究报告
该研究纳入1970至1999年确诊的6148例儿童急性淋巴细胞白血病(ALL)幸存者,按治疗方案与强度分为6组,比较全因及健康相关晚期死亡、后续恶性肿瘤、慢性健康状态与神经认知结局。标准风险1990年代样方案组健康相关晚期死亡与后续恶性肿瘤风险低于1970年代样方案组,20年严重慢性健康状况累积发生率更低,记忆与任务效率受损患病率更低。
要点
- 标准风险1990年代样方案组健康相关晚期死亡率低于1970年代样方案组(率比0.2)。
- 标准风险1990年代样方案组后续恶性肿瘤风险低于1970年代样方案组(率比0.3)。
- 标准风险1990年代样方案组20年严重慢性健康状况累积发生率11.0%,低于1970年代样方案组的22.5%。
核心结论
- 风险分层治疗降低了以标准风险1990年代样方案组为代表的当代标准风险ALL幸存者的晚期发病率与死亡率。
- 当代标准风险儿童ALL的5年幸存者健康相关晚期死亡与后续恶性肿瘤风险与美国一般人群相当。
研究设计与样本
- 儿童癌症幸存者研究纳入1970至1999年确诊的6148例儿童ALL幸存者,中位年龄27.9岁(范围5.9至61.9岁)。
- 按治疗方案组合与治疗强度分为6组:1970年代样(70s)、1980年代标准或高风险样(80sSR、80sHR)、1990年代样(90sSR、90sHR)及复发/移植(R/BMT)。
- 比较各组累积发生率、标准化死亡比与标准化发病比,并与美国人群比较。
主要发现
- 20年全因晚期死亡率为6.6%(95%CI 6.0至7.1)。
- 与70s组相比,90sSR组健康相关晚期死亡率更低(率比0.2,95%CI 0.1至0.4),90sHR组亦更低(率比0.3,95%CI 0.1至0.7)。
- 90sSR组标准化死亡比为1.3(95%CI 0.8至2.0),90sHR组为1.7(95%CI 0.7至3.5),与美国人群相当。
- 与70s组相比,90sSR组后续恶性肿瘤率更低(率比0.3,95%CI 0.1至0.6),标准化发病比为1.0(95%CI 0.6至1.6),与美国人群无差异。
- 90sSR组20年严重慢性健康状况累积发生率为11.0%(95%CI 9.7%至12.3%),低于70s组的22.5%(95%CI 19.4%至25.5%);记忆受损患病比为0.7(95%CI 0.6至0.9),任务效率受损患病比为0.5(95%CI 0.4至0.7)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Risk-stratified therapy, which modifies treatment on the basis of clinical and biologic features, has improved 5-year overall survival of childhood acute lymphoblastic leukemia (ALL) to 90%, but its impact on long-term toxicity remains unknown. METHODS: We assessed all-cause and health-related late mortality (including late effects of cancer therapy), subsequent malignant neoplasms (SMNs), chronic health conditions, and neurocognitive outcomes among 6,148 survivors of childhood ALL (median age, 27.9 years; range, 5.9-61.9 years) diagnosed between 1970 and 1999. Therapy combinations and treatment intensity defined 6 groups: 1970s-like (70s), standard- or high-risk 1980s-like (80sSR, 80sHR) and 1990s-like (90sSR, 90sHR), and relapse/transplantation (R/BMT). Cumulative incidence, standardized mortality ratios, and standardized incidence ratios were compared between treatment groups and with the US population. RESULTS: Overall, 20-year all-cause late mortality was 6.6% (95% CI, 6.0 to 7.1). Compared with 70s, 90sSR and 90sHR experienced lower health-related late mortality (rate ratio [95% CI]: 90sSR, 0.2 [0.1 to 0.4]; 90sHR, 0.3 [0.1 to 0.7]), comparable to the US population (standardized mortality ratio [95% CI]: 90sSR, 1.3 [0.8 to 2.0]; 90sHR, 1.7 [0.7 to 3.5]). Compared with 70s, 90sSR had a lower rate of SMN (rate ratio [95% CI], 0.3 [0.1 to 0.6]) that was not different from that of the US population (standardized incidence ratio [95% CI], 1.0 [0.6 to 1.6]). The 90sSR group had fewer severe chronic health conditions than the 70s (20-year cumulative incidence [95% CI], 11.0% [9.7% to 12.3%] v 22.5% [19.4% to 25.5%]) and a lower prevalence of impaired memory (prevalence ratio [95% CI], 0.7 [0.6 to 0.9]) and task efficiency (0.5 [0.4 to 0.7]). CONCLUSION: Risk-stratified therapy has reduced late morbidity and mortality among contemporary survivors of standard-risk ALL, represented by 90sSR. Health-related late mortality and SMN risks among 5-year survivors of contemporary, standard-risk childhood ALL are comparable to the general population.
引用
- Dixon SB, Chen Y, Yasui Y, et al. Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2020. PMID: 32706634. doi:10.1200/JCO.20.00493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。